Sanofi’s Diabetes Drug for Biosimilars dropped

U.S. pharmacy benefit manager CVS will lose Sanofi's primary insulin drug Lantus from the list of medications it reimburses on behalf of health insurance companies, dealing a blow to the French drugmaker's essential diabetes company. CVS said it'd change to the more affordable biosimilar drug Basaglar of Ely Lilly from 2017. Biosimilars are more affordable […]